As part of a new strategic initiative, aimed at strengthening its presence in cranberry derivatives, Indena has entered an industrial and commercial agreement with Pharmatoka.
On the basis of this agreement, Indena will produce Gikacran under exclusive license for Pharmatoka and will directly market Gikacran in Japan, South Korea, China, India and Russia. Gikacran is a well characterised cranberry juice (Vaccinium macrocarpon Ait.) extract, standardised so as to provide 17%-22% total proanthocyanidin (PAC) measured by DMAC method. 200 mg of Gikacran, containing 36 mg of cranberry proanthocyanidins (PACs), provide the same amount of PACs as found in 40 g of fresh fruits. Gikacran has been used since 2006 in different products in and outside Europe under the brand names Urell and Ellura. It is also available in Malaysia as a traditional herbal medicine.
